

Reference list on DDWAC as of September 5, 2017

1. Singh P, Madhaiyan K, Duong-Thi MD, Dymock BW, Ohlson S. Analysis of protein target interactions of synthetic mixtures by affinity-LC/MS. *Slas Discovery* 2017;22:440-6.
2. Ohlson S, Duong-Thi M-D. Weak affinity chromatography (wac). In: Huddler D, Zartler ER, eds. *Applied biophysics for drug discovery*, John Wiley & Sons, Ltd, 2017:107-30.
3. Ohlson S, Duong-Thi M-D. Emerging technologies for fragment screening. In: Erlanson DA, Jahnke W, eds. *Fragment-based drug discovery: Lessons and outlook*, Wiley-VCH Verlag, 2016:173-95.
4. Duong-Thi M-D, Bergstrom M, Edwards K, Eriksson J, Ohlson S, To Yiu Ying J, et al. Lipodisks integrated with weak affinity chromatography enable fragment screening of integral membrane proteins. *Analyst* 2016;141:981-8.
5. Duong-Thi M-D, Bergström G, Mandenius C-F, Bergström M, Fex T, Ohlson S. Notes & tips: Comparison of weak affinity chromatography and surface plasmon resonance in determining affinity of small molecules. *Analytical Biochemistry* 2014;461:57-9.
6. Duong-Thi MD, Bergström M, Fex T, Isakson R, Ohlson S. High-throughput fragment screening by affinity LC-MS. *J Biomolecular Screening* 2013;18:160-71.
7. Ramos-Soriano FJ, Niss U, Angelo J, Angel M, Moreno-Vargas AJ, Carmona AT, et al. Synthesis, biological evaluation, wac and nmr studies of s-galactosides and non-carbohydrate ligands of cholera toxin based on polyhydroxyalkylfuroate moieties *Chem Eur J* 2013;19:17989-8003.
8. Meiby E, Zetterberg MM, Ohlson S, Hernández VA, Edwards K. Immobilized lipodisks as model membranes in high-throughput HPLC-MS. *Anal Bioanal Chem* 2013;405:4859-69.
9. Meiby E, Simmonite H, le Strat L, Davis B, Matassova N, Moore JD, et al. Fragment screening by weak affinity chromatography: Comparison with established techniques for screening against hsp90. *Anal Chem* 2013;85:6756-66.
10. Duong-Thi MD, Bergström M, Fex T, Svensson S, Ohlson S, Isaksson R. Weak affinity chromatography for evaluation of stereoisomers in early drug discovery. *J Biomolecular Screening* 2013;18:748-55.
11. Bergström M, Åström E, Pålsson P, Ohlson S. Elucidating the selectivity of recombinant forms of aleuria aurantia lectin using weak affinity chromatography. *J of Chromatography B* 2012;885-886:66-72.
12. Landström J, Bergström M, Hamark C, Ohlson S, Widmalm G. Combining weak affinity chromatography, nmr spectroscopy and molecular simulations in carbohydrate-lysozyme interaction studies. *Organic & Biomolecular Chemistry* 2012;10:3019-32.
13. Meiby E, Knapp S, Elkins J, Ohlson S. Fragment screening of cyclin g-associated kinase by weak affinity chromatography. *Analytical and Bioanalytical Chemistry* 2012;404:2417-25.
14. Duong-Thi MD, Meiby E, Bergstrom M, Fex T, Isaksson R, Ohlson S. Weak affinity chromatography as a new approach for fragment screening in drug discovery. *Analytical Biochemistry* 2011;414:138-46.
15. Ohlson S, Duong-Thi MD, Bergström M, Fex T, Hansson L, Pedersen L, et al. Toward high-throughput drug screening on a chip-based parallel affinity separation platform. *J Sep Sci* 2010;33:1-7.
16. Bergstrom M, Liu S, Kiick KL, Ohlson S. Cholera toxin inhibitors studied with high-performance liquid affinity chromatography: A robust method to evaluate receptor-ligand interactions. *Chemical Biology & Drug Design* 2009;73:132-41.
17. Ohlson S. Designing transient binding drugs: A new concept for drug discovery. *Drug Discovery Today* 2008;13:433-9.

18. Ohlson S, Shoravi S, Fex T, Isaksson R. Screening for transient biological interactions as applied to albumin ligands: A new concept for drug discovery. *Analytical Biochemistry* 2006;359:120-3.
19. Zopf D, Ohlson S. Weak-affinity chromatography. *Nature* 1990;346:87-8.